Re-administration of pembrolizumab with prednisolone after pembrolizumab-induced nephrotic syndrome

Immune checkpoint inhibitors (ICIs) are associated with a unique spectrum of immune-related adverse events (irAEs) that are different from those occurring after conventional chemotherapy. Despite the risk of irAE recurrence, re-administration of ICIs after high-grade irAEs is critical, when considering their potential clinical benefits. Here, we report the first known case wherein pembrolizumab, an anti –programmed death 1 (PD-1) monoclonal antibody, was successfully re-administered with corticosteroids in a patient with severe nephrotic syndrome (NS) that developed during pembrolizumab therapy.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research